CNS Drugs

, Volume 24, Issue 3, pp 227–244

Intramuscular Paliperidone Palmitate

  • Sheridan M. Hoy
  • Lesley J. Scott
  • Gillian M. Keating
Adis Drug Profile

Abstract

Intramuscular paliperidone palmitate is a long-acting, atypical antipsychotic that is indicated in the US for the acute and maintenance therapy of adult patients with schizophrenia. Paliperidone is the major active metabolite of risperidone.

The noninferiority of flexible doses of intramuscular paliperidone palmitate 39–156 mg to flexible doses of intramuscular long-acting risperidone 25–50 mg was not established in an initial 53-week study. However, these data were utilized to optimize the intramuscular paliperidone palmitate dosage regimen.

In four randomized, double-blind studies, intramuscular paliperidone palmitate 39–234 mg was generally effective in the treatment of adult patients with acute schizophrenia, inducing significantly greater improvements from baseline in the mean Positive and Negative Syndrome Scale (PANSS) total score than placebo (primary endpoint).

In general, intramuscular paliperidone palmitate recipients achieved significantly better outcomes than placebo recipients with regard to the PANSS subscale, PANSS factor, Personal and Social Performance scale and Clinical Global Impressions-Severity scale scores.

As maintenance therapy, intramuscular paliperidone palmitate 39–156 mg was significantly more effective than placebo in delaying the time to the first relapse of schizophrenia symptoms in adult patients, according to the results of a randomized, double-blind study.

The beneficial effects of intramuscular paliperidone palmitate therapy on the PANSS total score were sustained in a 52-week noncomparative extension phase of the maintenance therapy study.

Intramuscular paliperidone palmitate 39–234 mg was generally well tolerated in adult patients with schizophrenia.

References

  1. 1.
    Lieberman JA, Fenton WS. Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 2000 Nov; 157(11): 1727–30PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization. Schizophrenia [online]. Available from URL: http://www.who.int/mental_health/management/schizophrenia/en/ [Accessed 2009 Jul 20]
  3. 3.
    Ho B-C, Alicata D, Mola C, et al. Hippocampus volume and treatment delays in first-episode schizophrenia. Am J Psychiatry 2005 Aug; 162(8): 1527–9PubMedCrossRefGoogle Scholar
  4. 4.
    Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004 Sep; 55(9): 997–1005PubMedCrossRefGoogle Scholar
  5. 5.
    Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1022–31PubMedCrossRefGoogle Scholar
  6. 6.
    Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007 Apr; 115(4): 260–7PubMedCrossRefGoogle Scholar
  7. 7.
    Fleischhacker WW, Gopal S, Samtani MN, et al. Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: results of two randomized double-blind studies and population pharmacokinetic simulations [poster]. American Psychiatric Association Annual Meeting; 2009 May 16–21; San Francisco (CA)Google Scholar
  8. 8.
    Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009; 48(9): 585–600PubMedCrossRefGoogle Scholar
  9. 9.
    Ortho-McNeil-Janssen Pharmaceuticals Inc. FDA approves Invega® Sustenna™ for the acute and maintenance treatment of schizophrenia [online]. Available from URL: http://www.janssen.com/janssen/news_release.html?item=073109_1 [Accessed 2009 Aug 5]
  10. 10.
    Ortho-McNeil-Janssen Pharmaceuticals Inc. Invega® Sustenna™ (paliperidone palmitate) extended-release injectible suspension: prescribing information [online]. Available from URL: http://www.invegasustenna.com/invegasustenna/shared/pi/invegasustenna.pdf [Accessed 2009 Aug 4]
  11. 11.
    Gopal S, Vijapurkar U, Lim P, et al. Long-term efficacy, safety, and tolerability of paliperidone palmitate in patients with schizophrenia [abstract no. NR1-031 plus poster]. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2009 Apr 19–22; Jacksonville (FL)Google Scholar
  12. 12.
    Yang LP, Plosker GL. Paliperidone extended release. CNS Drugs 2007; 21(5): 417–25; discussion 426-7PubMedCrossRefGoogle Scholar
  13. 13.
    Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects [abstract no. P.1.053]. Eur Neuropsychopharmacol 2005 Oct; 15Suppl. 3: S 386. Plus poster presented at the 18th European Congress of Neuropsychopharmacology; 2005 Oct 22–26; AmsterdamGoogle Scholar
  14. 14.
    Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006 Mar; 163(3): 396–401PubMedCrossRefGoogle Scholar
  15. 15.
    Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000 Apr; 157(4): 514–20PubMedCrossRefGoogle Scholar
  16. 16.
    Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999 Feb; 156(2): 286–93PubMedGoogle Scholar
  17. 17.
    Pandina G, Lindenmayer J, Lull J, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess efficacy and safety of paliperidone palmitate in adult subjects with schizophrenia [abstract plus poster]. 12th International Congress on Schizophrenia Research; 2009 Mar 28–Apr 1; San Diego (CA)Google Scholar
  18. 18.
    Cleton A, Rossenu S, Hough D, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles [abstract no. PI-74]. Clin Pharmacol Ther 2008 Mar; 83Suppl. 1: S 31. Plus poster presented at the American Society for Clinical Pharmacology and Therapeutics; 2008 Apr 2–5; Orlando (FL)Google Scholar
  19. 19.
    Cleton A, Rossenu S, Hough D, et al. Evaluation of the pharmacokinetic profile of gluteal versus deltoid intramuscular injections of paliperidone palmitate 100mg equivalent in patients with schizophrenia [abstract no. PI-75]. Clin Pharmacol Ther 2008 Mar; 83Suppl. 1: S 31. Plus poster presented at the American Society for Clinical Pharmacology and Therapeutics; 2008 Apr 2–5; Orlando (FL)Google Scholar
  20. 20.
    Kern-Sliwa J, Samtani MN, Haskins JT, et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation [abstract no. NR1-046 plus poster]. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2009 Apr 19–22; Jackonville (FL)Google Scholar
  21. 21.
    Haskins JT, Samtani MN, Alphs L, et al. Maintenance dosing of once-monthly (4-weekly) paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on population simulations [abstract no. NR1-036 plus poster]. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2009 Apr 19–22; Jacksonville (FL)Google Scholar
  22. 22.
    Samtani MN, Gopal S, Kern-Sliwa J, et al. Management of missed paliperidone palmitate doses based on pharmacokinetic modeling and simulation [poster]. 49th Annual New Clinical Drug Evaluation Unit Meeting; 2009 Jun 29–Jul 2; Hollywood (FL)Google Scholar
  23. 23.
    Nasrallah HA, Gopal S, Quiroz JA, et al. Efficacy and safety of three doses of paliperidone palmitate, an investigational long-acting injectable antipsychotic, in schizophrenia [abstract NR4-036 plus poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DCGoogle Scholar
  24. 24.
    Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. Epub 2009 Nov 27Google Scholar
  25. 25.
    Johnson & Johnson Pharmaceutical Research & Development L.L.C. A study to evaluate the effectiveness and safety of 3 doses of paliperidone palmitate in treating subjects with schizophrenia [ClinicalTrials.gov identifier NCT00210548]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Oct 8]
  26. 26.
    Johnson & Johnson Pharmaceutical Research & Development L.L.C. A study to evaluate the effectiveness and safety of 3 doses of paliperidone palmitate in treating subjects with schizophrenia [online]. Available from URL: http://download.veritasmedicine.com/PDF/CR002353_CSR.pdf [Accessed 2009 Oct 8]
  27. 27.
    Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. Epub 2009 Dec 1Google Scholar
  28. 28.
    Johnson & Johnson Pharmaceutical Research & Development L.L.C. Efficacy and safety of a long acting anti-psychotic versus placebo in patients with schizophrenia [ClinicalTrials.gov identifier NCT00101634]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Dec 15]
  29. 29.
    Johnson & Johnson Pharmaceutical Research & Development L.L.C. Efficacy and safety of a long acting anti-psychotic versus placebo in patients with schizophrenia [online]. Available from URL: http://download.veritasmedicine.com/PDF/CR003562_CSR.pdf [Accessed 2009 Dec 15]
  30. 30.
    Alphs L, Bossie C, Kern-Sliwa J, et al. Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness [abstract no. NR6-027 plus poster]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16–21; San Francisco (CA)Google Scholar
  31. 31.
    Data on file, Ortho-McNeil-Janssen Pharmaceuticals Inc., 2009Google Scholar
  32. 32.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  33. 33.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000Google Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Sheridan M. Hoy
    • 1
  • Lesley J. Scott
    • 1
  • Gillian M. Keating
    • 1
  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754New Zealand

Personalised recommendations